SBRA 31012

Drug Profile

SBRA 31012

Latest Information Update: 08 Apr 2003

Price : $50

At a glance

  • Originator Roswell Park Cancer Institute; State University of New York at Stony Brook
  • Class Antineoplastics; Taxanes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 08 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 17 Jul 2001 This compound is still in active development
  • 16 May 1997 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top